Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: LHC Group (LHCG), Sarepta Therapeutics (SRPT) and Homology Medicines (FIXX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on LHC Group (LHCGResearch Report), Sarepta Therapeutics (SRPTResearch Report) and Homology Medicines (FIXXResearch Report).

LHC Group (LHCG)

RBC Capital analyst Ben Hendrix maintained a Hold rating on LHC Group on May 16 and set a price target of $170.00. The company’s shares closed last Tuesday at $165.90.

According to TipRanks.com, Hendrix is a 1-star analyst with an average return of -4.5% and a 36.6% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Bright Health Group.

LHC Group has an analyst consensus of Hold, with a price target consensus of $166.73.

See the top stocks recommended by analysts >>

Sarepta Therapeutics (SRPT)

In a report issued on May 16, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics, with a price target of $155.00. The company’s shares closed last Tuesday at $71.30.

According to TipRanks.com, Abrahams has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.0% and a 41.2% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Corbus Pharmaceuticals.

Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $119.67, representing a 74.1% upside. In a report issued on May 4, Robert W. Baird also maintained a Buy rating on the stock with a $110.00 price target.

Homology Medicines (FIXX)

In a report issued on May 16, Luca Issi from RBC Capital maintained a Hold rating on Homology Medicines, with a price target of $4.00. The company’s shares closed last Tuesday at $1.51, close to its 52-week low of $1.39.

According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -30.3% and a 17.4% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Homology Medicines is a Moderate Buy with an average price target of $10.64, representing a 644.1% upside. In a report released yesterday, Credit Suisse also maintained a Hold rating on the stock with a $2.10 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LHCG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos